Are synairgen shares worth buying?

Are synairgen shares worth buying?

Synairgen plc (SNG) is a leading biotechnology business based in the UK. In the week up to 4 December Synairgen shares surged 12.67% to a closing position of 193.8p. Over the last 12 months, Synairgen’s share price has risen by an impressive 98.17% from 98.5p….Synairgen shares at a glance.

Open	171p
Volume	5,151,113

Why have synairgen shares gone up?

The Synairgen (LSE: SNG) share price has jumped in early deals this morning after the company published an update on the trials of its coronavirus treatment. Over the past two years, the group has been testing SNG001, a formulation containing the antiviral protein interferon beta, to treat the virus.

Is syn a good buy?

Synthetic Biologics Inc (SYN) stock is down -10.53% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. This means analysts expect the stock to rise 194.12% over the next 12 months. The short-term technical score for SYN is 61. SYN has an Overall Score of 79.

Why has synairgen share price dropped?

Synairgen shares drop as AstraZeneca stops asthma drug study AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in patients with asthma upon onset of common cold symptoms. Synairgen’s shares dropped 32.35% to 23p at 1624 BST on Wednesday.

Should I invest in synthetic biologics?

There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Synthetic Biologics stock.

Is Synthetic Biologics a good stock to buy?

Is Synthetics Biologics Inc stock A Buy? Synthetics Biologics Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Is syn stock a good buy?

What does SYN company do?

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need.

Is Synthetic Biologics a good buy?

Synthetic Biologics Inc (SYN) stock is down -10.53% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives SYN stock a score of 79 out of a possible 100.

What does Synthetic Biologics Inc do?

Synthetic Biologics, Inc. is a clinical stage company developing therapeutics which protect microbiomes and target pathogen-specific diseases.

Is Synthetic a good stock?

While options have the ability to limit a trader’s total investment, options also expose traders to volatility, risk, and adverse opportunity cost. Given these limitations, a synthetic option may be the best choice when making exploratory trades or establishing trading positions.

What was the last closing price for synairgen plc?

The last closing price for Synairgen was 158p. Synairgen Plc has a 4 week average price of 140p and a 12 week average price of 138.50p. The 1 year high share price is 234p while the 1 year low share price is currently 75p.

How do I buy shares in synairgen?

To buy shares in Synairgen, you’ll need to have an account. Try our handy filter to explore the different options. Ready to invest? To invest in Synairgen, you’ll need to open an account. Try our handy filter to find which one suits you best.

What is synairgen developing with Pharmaxis?

Synairgen has collaborated with Australian pharmaceutical research company Pharmaxis to develop small molecule inhibitors of LOXL2 for the treatment of fibrotic disease. Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

What is synsynairgen plc’s share price?

Synairgen Plc has a 4 week average price of 9.25p and a 12 week average price of 9.25p. The 1 year high share price is 18.50p while the 1 year low share price is currently 9.25p. There are currently 109,433,442 shares in issue and the average daily traded volume is 21,857 shares.